HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jcp.2006.042747v1 59/12/1334    most recent Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palmieri, C Articles by Vigushin, D Search for Related Content PubMed PubMed Citation Articles by Palmieri, C Articles by Vigushin, D

Serum 25-hydroxyvitamin D levels in early and advanced breast cancer

¹ Cancer Research UK Laboratories, Department of Cancer Medicine, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
² Department of Metabolic Medicine, Faculty of Medicine, Imperial College London, London, UK

Correspondence to:
C Palmieri
Cancer Research UK Laboratories, Department of Cancer Medicine, MRC Cyclotron Building, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK; c.palmieri{at}imperial.ac.uk
ABSTRACT
Background: Laboratory and epidemiological studies have implicated vitamin D deficiency in the pathogenesis of breast cancer. 1,25-Dihydroxyvitamin D (1,25(OH)₂D) promotes differentiation and apoptosis, and potently inhibits proliferation of malignant breast epithelial cells in culture. Serum levels of 1,25(OH)₂D are higher in normal women than in patients with primary breast cancer.

Aim: To clarify the role of vitamin D in breast cancer progression by comparing the levels of serum vitamin D in patients with early and in those with advanced breast cancer.

Methods: Circulating levels of 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH) and calcium were measured prospectively in 279 Caucasian women with invasive breast cancer, 204 women with early-stage disease and 75 women with locally advanced or metastatic disease.

Results: Patients with early-stage breast cancer had significantly higher circulating levels of 25(OH)D (p<0.005) and significantly lower PTH (p<0.001) levels than those with advanced disease. Calcium levels did not differ significantly (p = 0.74).

Conclusion: Serum levels of 25(OH)D are significantly higher in patients with early-stage breast cancer than in those with locally advanced or metastatic disease.

Abbreviations: 1, 25(OH)₂D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone

This article has been cited by other articles:

				I. Cantor Shedding Light on Vitamin D and Integrative Oncology Integr Cancer Ther, June 1, 2008; 7(2): 81 - 89. [Abstract] [PDF]

				E. M. John, G. G. Schwartz, J. Koo, W. Wang, and S. A. Ingles Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Breast Cancer Risk in a Multiethnic Population Am. J. Epidemiol., December 15, 2007; 166(12): 1409 - 1419. [Abstract] [Full Text] [PDF]

				P. Autier and S. Gandini Vitamin D Supplementation and Total Mortality: A Meta-analysis of Randomized Controlled Trials Arch Intern Med, September 10, 2007; 167(16): 1730 - 1737. [Abstract] [Full Text] [PDF]

eLetters: